

UNITED STATES PATENT AND TRADEMARK OFFICE
Trademark Trial and Appeal Board
P.O. Box 1451
Alexandria, VA 22313-1451

kk

Mailed: February 27, 2012

Opposition No. 91202031

Regeneron Pharmaceuticals, Inc.

v.

Argos Therapeutics, Inc.

**Robert H. Coggins,
Interlocutory Attorney:**

On February 13, 2012, applicant filed a proposed amendment to its application Serial No. 77174310, with opposer's consent.

By the proposed amendment applicant seeks to change the identification of goods in Class 5 **from** "Pharmaceutical preparations, vaccines and biologics for the treatment of cancer, infectious diseases, transplantation and auto-immune diseases" **to** "Cell preparations, cellular vaccines and cellular biologics for the treatment of cancer and infectious diseases by autologous cell-based immunotherapy"; and the recitation of services in Class 42 **from** "Research and development services for others in the field of human diseases and vaccines" **to** "Research and development for others in the field of human diseases and vaccines, namely, research and development of cell preparations, cellular vaccines, and

Opposition No. 91202031

cellular biologics for the treatment of cancer and infectious diseases by autologous cell-based immunotherapy."

Inasmuch as the amendment is limiting in nature as required by Trademark Rule 2.71(a), and because opposer consents thereto, it is approved and entered. See Trademark Rule 2.133(a).

If this resolves the dispute between the parties, opposer is allowed until twenty days from the mailing date of this order to file a withdrawal of the opposition, failing which the opposition will go forward on the application as amended. See Trademark Rule 2.106(c).

Dates otherwise remain as set.